Abstract
Background Wuhan, China was the epicenter of the 2019 coronavirus outbreak. As a designated hospital, Wuhan Pulmonary Hospital has received over 700 COVID-19 patients. With the COVID-19 becoming a pandemic all over the world, we aim to share our epidemiological and clinical findings with the global community.
Methods In this retrospective cohort study, we studied 340 confirmed COVID-19 patients from Wuhan Pulmonary Hospital, including 310 discharged cases and 30 death cases. We analyzed their demographic, epidemiological, clinical and laboratory data and implemented our findings into an interactive, free access web application.
Findings Baseline T lymphocyte Subsets differed significantly between the discharged cases and the death cases in two-sample t-tests: Total T cells (p < 2·2e-16), Helper T cells (p < 2·2e-16), Suppressor T cells (p = 1·8-14), and TH/TS (Helper/Suppressor ratio, p = 0·0066). Multivariate logistic regression model with death or discharge as the outcome resulted in the following significant predictors: age (OR 1·05, p 0·04), underlying disease status (OR 3·42, p 0·02), Helper T cells on the log scale (OR 0·22, p 0·00), and TH/TS on the log scale (OR 4·80, p 0·00). The McFadden pseudo R-squared for the logistic regression model is 0·35, suggesting the model has a fair predictive power.
Interpretation While age and underlying diseases are known risk factors for poor prognosis, patients with a less damaged immune system at the time of hospitalization had higher chance of recovery. Close monitoring of the T lymphocyte subsets might provide valuable information of the patient’s condition change during the treatment process. Our web visualization application can be used as a supplementary tool for the evaluation.
Funding The authors report no funding.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors report no funding.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.
